IKang Guobin Healthcare Group Submitted Application To The SEC For Nasdaq IPO
This article was originally published in PharmAsia News
Ikang Guobin Healthcare Group, a medical examination and health management service provider, has submitted its IPO application to U.S. SEC to be listed on NASDAQ, aiming to raise up to $150 million during its IPO.
You may also be interested in...
Novartis seems to have accepted the fact that the indication granted for Piqray in the EU means there is little scope for the advanced breast cancer drug to be used in markets such as the UK.
Generic OTC paracetamol and ibuprofen pack prices are gradually returning to pre-COVID levels, according to market analysts Wavedata. But a second wave could drive prices back up again.
Latest EU company news: Sanofi grows OTC portfolio in France and Italy with ColdZyme; Germany's WindStar Medical gets UK owners; and France's Ipsen continues to fell effects of COVID-19 on sales.